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Prolonged Remission of Cushing's Disease Following
Bromocriptine Therapy
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Malachi J. McKenna, MD,* Marc Linares, MD,^ and Raymond C. Mellinger, MD*

A 33-year-old woman developed hypercorticism of fulminant onset following delivery ofa full-term,
norrruil child. An ectopic hormone-producing neoplasm was excluded by extensive studies. Pituitarydependent hypercorticism of intermediate lobe origin was suggested on the basis of onset following
pregnancy, failure of Cortisol suppression by high-dose dexamethasone, hyperresponsiveness of
prolactin to thyrotropin-releasing hormone stimulation, and reduction in adrenocorticotropin titers
following oral administration of bromocriptine. Initial remission of disease achieved with
bromocriptine was followed by recurrence on discontinuation ofthe agent. However, complete
remission which occurredfollowing a prolonged course of bromocriptine has persistedfor a total of22
months. (Henry FordHosp MedJ 1987:35:188-91)

P

ituitary-dependent adrenocortical hyperplasia, Cushing's
disease, is the most common cause of spontaneous hypercorticism (1). Some believe that the primary abnormality resides
in the anterior pituitary, usually manifested by a corticotroph
adenoma. However, recent studies suggest that in a number of
cases hypothalamic dysfunction is the primary abnormality
leading to corticotroph proliferation (2,3). A variety of neurotransmitters and neuropeptides have been implicated in this
process, and chemotherapeutic agents that affect hypothalamic
regulation of ACTH secretion may play a role in treatment (2).
One such agent, bromocriptine, has been shown by different investigators to induce temporary remission in some patients
(3-11). We report a case of a patient with Cushing's disease in
whom prolonged remission has been attained following bromocriptine therapy.

Case Report
A 33-year-old white female presented with hypercorticism of fulminant onset. Seven weeks previously she had delivered a full-term, normal child. The pregnancy and delivery were unremarkable, and she
received a medication (probably bromocriptine) to prevent postpartum
lactation. A few days thereafter she noted the onset of tongue swelling,
and the medication was discontinued because of a presumed allergic
reaction. However, over the next six weeks she developed severe emotional symptoms including nervousness, irritability, depression, sleeplessness, and unpredictable activity. She became weaker, and noted
thinning of her extremities, easy bruisibility, and increasing enlargement of her face, neck, and trunk. She experienced severe polydipsia
and muscle cramps, and her weight increased by 6 kg infivedays. After
an episode of rectal bleeding, she attended an emergency room for evaluation and was admitted to the community hospital. Sigmoidoscopic
and colon x-ray examinations were negative, but hypokalemia was
noted and Cushing's syndrome was suspected. Serum Cortisol was
elevated at 56 |xg/dL, so she was referred to us for evaluation. When admitted to Henry Ford Hospital six weeks after delivery, she was noted to
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be plethoric with facial rounding, supraclavicular fullness, and a modest cervicodorsal pad. Her proximal muscles were weak, and she hada
number of ecchymoses. Several flat, blackened moles of recent onset
were seen on her anterior chest, and diffuse pigmentation was present
over her gums, face, nipples, and dorsum of hands and feet. However,
the patient maintained that her complexion, always dark, had not
changed. Blood pressure was 130/78 mm Hg.
Initial studies revealed a high serum Cortisol of 31 (xg/dL in the afternoon, associated with a high ACTH level of 97 pg/mL (Figure). Urinefree Cortisol values were 257 and 412 |a-g/24 hours. Semm potassium
was low at 2.5 mEq/L, but this abnormality was readily corrected by a
small, oral dose of potassium chloride. In view of the precipitous onset
of the disorder, the unexplained rectal bleeding, and the low serum potassium, an ectopic hormone-producing neoplasm was suspected as the
cause of the disorder However, no tumor was identified by extensive
studies which included abdominal computed tomography and a visceral
angiogram. Computed tomography of the sella turcica was inlerpreted
as demonstrating pituitary enlargement, which, however, was considered to be compatible with the patient's postpartum state. No intrasellar abnormality was described. For personal reasons the patient was
discharged from the hospital, and interval medical management was
initiated with 250 mg of aminoglutethimide four times daily. This medication was stopped one week later, and the patient was readmitted ftt
further studies. Two weeks later, aminoglutethimide therapy was
restarted and continued for another three weeks. Serum Cortisol fellt"
13 |xg/dL. Although her weakness and edema improved, she complained of scalp hair loss, and aminoglutethimide therapy was stopped'
Without treatment, weakness and facial swelling recurred; the patie"'
developed acne and seemed increasingly hyperpigmented. Serum cof'
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Three provocative tests were performed: 1) a high-dose dexamethasone study, 2) a combined thyrotropin-releasing hormone
and gonadotropin-releasing hormone test, and 3) an oral bromocriptine challenge. For the dexamethasone suppression
study, the patient received 2 mg orally every six hours for three
(jays following three days of baseline studies. Serum and urine
Cortisol were measured daily, and serum ACTH was measured
prior to and on completion of the tests. Thyrotropin-releasing
hormone (200 ixg) and gonadotropin-releasing hormone (IOO
|j,g) were administered together intravenously during the second
course of aminoglutethimide. Blood was drawn at 0, 15, and 30
minutes for estimation of ACTH, prolactin, luteinizing hormone, and thyroid-stimulating hormone. The patient received
the oral test dose of bromocriptine (2.5 mg) ten days after stopping the second course of aminoglutethimide. Blood was drawn
at 0 and 240 minutes for estimation of ACTH and (i-endorphin.
The following substances were measured by standard radioimmunoassay techniques: Cortisol (reference range: 8 to 28 (xg/
dL in serum, and < 120 |xg/24 hr in urine [Amerlex, IL]); prolactin (reference range: < 25 ng/mL [Abbot, IL]); thyroid-stimulating hormone (reference range: < 5 |xIU/mL [Leeco, MI]);
and luteinizing hormone (basal range of 4 to 29 |xIU/mL [Leeco,
Ml]). Serum ACTH was measured at the Nichols Institute with
expected moming values of < 130 pg/mL. Serum p-endorphin
and concomitant ACTH titers were measured using previously
described techniques (12,13). Serum P-endorphin is not detectable in healthy adults by this assay, which has a sensitivity of 5
femtomole/mL.

Results
A paradoxical response occurred with the dexamethasone
test. Twenty-four hour urinary Cortisol excretion, corrected for
creatinine levels, rose remarkably to 2,779, 5,(M3, and 3,724
^% from baseline values of 394 and 359 |xg. On completion of
the study, serum ACTH (160 pg/mL) was also higher than the
baseline values of 129, 131, and 115 pg/mL. The effect of the
prior one week of aminoglutethimide therapy on this unusual response is not known, but the rise in ACTH titer which occurred
contemporaneously with the rise in urinary Cortisol substantiates the failure of pituitary suppression by dexamethasone.
Following combined thyrotropin- and gonadotropin-releasing
hormone administration, serum ACTH levels did not change
(baseline = 99 pg/mL; 15 min = 83 pg/mL; 30 min = 81
Pg/mL). The serum prolactin, however, rose from 14 to 120 ng/
f L at 30 minutes, while the serum luteinizing hormone rose
from 9.5 to 52.3 ixIU/mL at 30 minutes, and the thyroid-stimtlating hormone rose from 1.7 to 5.1 p,IU/mL. Following the
°fal dose of bromocriptine, serum ACTH fell from 106 to 50 pg/
"tL at 240 minutes, while serum p-endorphin decreased slightly
from an elevated value of 14 to 12.6 fm/mL.
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Figure—Biochemical response to bromocriptine (BC) therapy.
The stippled areas represent reference ranges. The asterisk indicates a period of symptomatic relapse during therapy.

Response to Bromocriptine Therapy
Eighteen weeks after delivery and six weeks after stopping
the second course of aminoglutethimide, bromocriptine therapy
was introduced beginning with 5 mg/day for one week, increasing to 7.5 mg/day for nine weeks, and then gradually reducing
the dose over the next four weeks. During this period of therapy,
serum Cortisol, urinary Cortisol, and serum ACTH levels were
consistently within the normal reference ranges (Figure), and
another computed tomography examination of the sella was
within normal limits. The patient felt well, scalp hair regrew, all
physical signs of Cushing's syndrome disappeared, and regular
menses returned. Despite presumption that the remission of
Cushing's disease had been induced by bromocriptine, the possibility that the patient had had a transient form of the disorder
merited consideration, and bromocriptine therapy was withdrawn after more than three months of treatment. Within four
weeks, facial swelling recurred. Moreover, there was convincing biochemical evidence for recurrent hypercorticism (Figure).
Accordingly, bromocriptine therapy was reinstituted and continued without interruption for 17 months. During this continuous therapy, the patient reported four episodes of weight gain
and facial swelling accompanied by insomnia and overactivity.
During the most severe episode, which occurred after five
months of continuous therapy, urine-free Cortisol was elevated to
557 |xg/dL (Figure). However, the clinical abnormalities rapidly
abated without change in bromocriptine treatment, and the
markedly increased urinary Cortisol subsided. On another occasion, when the patient neglected to take bromocriptine for
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ten days, she reported weight gain, weakness, and nocturia,
symptoms which resolved within five days after restarting bromocriptine. After a six-month period during which urinary Cortisol values were continuously normal and the patient experienced no hypercortical symptoms, bromocriptine therapy was
discontinued. The total duration of therapy had been 22 months.
To date, more than two years later, her condition has remained in
remission. At no time were there any side effects attributed to
bromocriptine treatment.

Discussion
This unusual case of Cushing's disease presented in a fulminant manner suggestive of an ectopic neuroendocrine tumor, but
with the passage of time displayed an indolent course and completely resolved following a period of bromocriptine therapy.
Since the rapid onset of her disease occurred within a few days
after a normal, term pregnancy, some relationship merits consideration. Remission of hypercorticism during pregnancy, followed by postpartum relapse, has been previously documented
(14-16). During normal pregnancy, ACTH levels are suppressed, possibly through the direct suppressive effect on the
pituitary of placental estrogens and progesterone (17). Cortisol
levels in serum are strikingly elevated because of the threefold to
fourfold elevation in the cortisol-binding globulin. Conceivably,
physiologic adjustment in the immediate postpartum period
could release large quantities of Cortisol bound to cortisol-binding globulin, while the termination of ACTH suppression could
be conducive to the development of Cushing's disease. Possibly
of even greater importance is the known development of the
intermediate lobe of the pituitary during pregnancy (18).
Based upon aiumal and human studies, Krieger (2) suggested
that Cushing's disease in man may originate from corticotroph
cells in either the anterior pituitary or the intermediate lobe, and
that the two disorders may present different functional characteristics and responses to different therapeutic maneuvers. A
distinct intermediate lobe, present in the human fetus in rudimentary form, disappears after birth (19). However, the corticotroph cells residing in the zona intermedia may proliferate
during pregnancy (18). Corticotrophs in the anterior lobe produce a 16 K protein, ACTH, and 3-lipotropin from the precursor
molecule peoopiomelanocortin (20). In the intermediate lobe,
further proteolytic cleavage yields a-melancx;yte-stimulating
hormone derived from ACTH, and p-endorphin derived from
P-lipotropin. The factors regulating ACTH production are also
different in the two lobes. In the anterior lobe, ACTH synthesis
is increased by corticotropin-releasing hormone, antidiuretic
hormone, and insulin-induced hypoglycemia, but is decreased
by glucocorticoids. Intermediate lobe corticotrophs are little
affected by these stimuli, and have a low concentration of
the Cortisol receptor (21). However, ACTH synthesis in the
intermediate lobe is apparently inhibited by dopamine (2,21).
These experimental data have prompted investigations designed to identify Cushing's disease patients with hypothalamic
dysregulation who might be treated with chemotherapeutic
agents (2). Lamberts et al (3) have provided substantial evidence
supporting the hypothesis that Cushing's disease may arise in
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corticotrophs of intermediate lobe origin. In six of 15 Cushing's
disease patients who had transsphenoidal surgery, histological
analysis after argyrophilic staining revealed neural tissue in tl)»
midst of the adenomas. Compared to cases lacking neurofibers
these six subjects responded to a single oral dose of bromocrip.
tine with a reduction in serum ACTH, had reduced respoQ.
siveness to dexamethasone, were more likely to have hypej.
prolactinemia, and were less likely to attain a remission
following pituitary surgery. In two instances, the adenomas
were situated adjacent to the pars nervosa in the region of the
zona intermedia. Our case was similar to these six cases in that
there was failure of Cortisol suppression by high-dose dexamethasone, hyperresponsiveness of prolactin to thyrotropinreleasing hormone stimulation, and a reduction in ACTH titers
following a single dose of bromocriptine. Our patient
did not demonstrate an ACTH response to thyrotropin-releasing
hormone, but it is disputed whether such a response occurs in
patients with Cushing's disease of intermediate lobe origin
(22). Indeed, the very concept of intermediate lobe origin for
Cushing's disease continues to be disputed (23).
The efficacy of bromocriptine in the management of
Cushing's disease both in the short and long term has been evaluated by many investigators with variable results. In about 50%
of 49 cases reported in six different series, a single dose of 2.5
mg of bromocriptine resulted in lower ACTH levels (3-7,24). It
is uncertain whether the acute response to dopamine agonists
relates to the outcome of long-term therapy, but certainly the response to long-term treatment has not been favorable. Reported
remissions are usually incomplete and temporary (4-10). One reported patient with prolonged remission required continuous
therapy (11). Our patient, with a complete remission achieved
following a prolonged course of bromocriptine therapy, is
unique. However, her course was marked by four brief relapses
even while taking bromocriptine. We speculate that our patieni
had self-limited hypothalamic dysfunction, which was responsive to dopamine repletion but which periodically escaped
therapeutic control.
This case report testifies to the complex nature of Cushing s
disease, consistent with recent insights into the control of
ACTH synthesis in the pituitary. Dopamine agonists should be
considered as a means of medical therapy in the management of
the disorder, particularly in cases associated with hyperprolactinemia and reduced responsiveness to dexamethasone. If ^
favorable biochemical response is observed in the short term,
a trial of therapy should be instituted. Apparently, if surgery
becomes necessary in a bromocriptine responder, total hypoph'
ysectomy is required to secure a remission (3).
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